Literature DB >> 27451257

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.

Elodie Lohou1, N André Sasaki2, Agnès Boullier3, Pascal Sonnet1.   

Abstract

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu(2+)-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AGE (Advanced Glycation Endproducts); ALE (Advanced Lipid peroxidation Endproducts); Alzheimer's disease; Biometal dyshomeostasis; Carbonyl stress; Diamine building blocks; Hydroxypyridinone (HOPO) ligands; Oxidative stress; Phenolic acids

Mesh:

Substances:

Year:  2016        PMID: 27451257     DOI: 10.1016/j.ejmech.2016.04.069

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans.

Authors:  Ilaria Marrocco; Fabio Altieri; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2017-06-18       Impact factor: 6.543

2.  Hydroxypyridinone-Diamine Hybrids as Potential Neuroprotective Agents in the PC12 Cell-Line Model of Alzheimer's Disease.

Authors:  Elodie Lohou; N André Sasaki; Agnès Boullier; Marine Duplantier; Pascal Sonnet
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.